Triptorelin for the relief of lower urinary tract symptoms in men with advanced prostate cancer: results of a prospective, observational, grouped-analysis study.

about

Triptorelin relieves lower urinary tract symptoms in Chinese advanced prostate cancer patients: a multicenter, non-interventional, prospective study.

P2860

Q51733811-9E358F59-02CA-4724-846D-43E4E6005BE0

P2860

Triptorelin for the relief of lower urinary tract symptoms in men with advanced prostate cancer: results of a prospective, observational, grouped-analysis study.

Item

http://www.wikidata.org/entity/Q38658856

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Triptorelin for the relief of ...... ional, grouped-analysis study.

@en

type

Item

label

Triptorelin for the relief of ...... ional, grouped-analysis study.

@en

prefLabel

Triptorelin for the relief of ...... ional, grouped-analysis study.

@en

P1476

Triptorelin for the relief of ...... ional, grouped-analysis study.

@en

P2093

Fouad Aoun

http://www.w3.org/2001/XMLSchema#string

Patrick Cabri

http://www.w3.org/2001/XMLSchema#string

Roland van Velthoven

http://www.w3.org/2001/XMLSchema#string

Thierry Gil

http://www.w3.org/2001/XMLSchema#string

Valérie Perrot

http://www.w3.org/2001/XMLSchema#string

P2860

Symptomatic diagnosis of prostate cancer in primary care: a structured review.

Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.

Benign prostatic hyperplasia and prostate cancer.

Construct validation of patient global impression of severity (PGI-S) and improvement (PGI-I) questionnaires in the treatment of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.

Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus

Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233).

A prospective, observational grouped analysis to evaluate the effect of triptorelin on lower urinary tract symptoms in patients with advanced prostate cancer.

EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines).

Gonadotropin-releasing hormone agonists in the treatment of prostate cancer.

P304

179-190

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1756287217712379

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28747996

http://www.w3.org/2001/XMLSchema#string

P932

5510771

http://www.w3.org/2001/XMLSchema#string

Triptorelin for the relief of lower urinary tract symptoms in men with advanced prostate cancer: results of a prospective, observational, grouped-analysis study.

about

P2860

P2860

Triptorelin for the relief of lower urinary tract symptoms in men with advanced prostate cancer: results of a prospective, observational, grouped-analysis study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932